Prospective Cohort Study of Pheochromocytoma/Paraganglioma
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-99
SponsorPeking Union Medical College Hospital
About this trial
The study will enroll patients scheduled for PPGL removal surgery at Peking Union Medical College Hospital. Before surgery, researchers will use a 6-variable model to predict the patient's risk of experiencing severe blood pressure swings during the operation. During surgery, a real-time early warning tool will be tested for its ability to accurately predict blood pressure changes 60 seconds in advance. The study will also explore the value of continuous glucose monitoring (CGM) in understanding blood pressure fluctuations and evaluate the performance of an artificial intelligence (AI) agent for preoperative anesthesia assessment, comparing its accuracy, consistency, and efficiency against that of human anesthesiologists.
Participation involves no changes to the patient's standard surgical or medical care. It includes collecting clinical data, wearing a CGM sensor from the day before to the day after surgery, and having the preoperative assessment performed by both the AI agent and anesthesiologists.
Eligibility criteria
Qualifiers
Age ≥ 18 years.
Diagnosed with pheochromocytoma/paraganglioma by imaging and laboratory tests and scheduled for elective resection.
Planned intraoperative continuous invasive arterial pressure monitoring.
Willing and able to provide written informed consent.
Disqualifiers
Intraoperative hemodynamic data missing ≥20%.
Postoperative histopathology excludes PPGL diagnosis.
Cardiac paraganglioma or metastatic PPGL.
Severe cardiac disease (e.g., severe valvular disease, severe heart failure) that could independently cause intraoperative HDI.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
200 Participants
are grouped into 1 trial groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov